南财智讯9月3日电，复星医药（02196.HK）公告，公司控股子公司上海复宏汉霖生物技术股份有限公司的地舒单抗注射液（商品名：BILDYOS®60mg/mL,BILPREVDA®120mg/1.7mL）已获得美国食品药品监督管理局（FDA）批准，用于多种适应症，包括治疗骨折高风险的绝经后妇女骨质疏松症、男性骨质疏松症、糖皮质激素引起的骨折高风险的男女骨质疏松症、接受雄激素剥夺治疗的非转移性前列腺癌男性患者的增加骨量治疗、接受芳香化酶抑制剂辅助治疗的乳腺癌女性患者的增加骨量治疗、预防多发性骨髓瘤患者和实体肿瘤的骨转移患者中发生骨相关事件的风险、治疗不可手术切除或手术切除后可能导致严重功能障碍的骨巨细胞瘤患者，以及治疗接受双膦酸盐治疗后出现的难治性恶性肿瘤高钙血症。
（文章来源：南方财经网）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.